GLUE affiliate files Form 144 for June stock sales

GLUE affiliate submitted a Form 144 notice disclosing proposed and recent sales of Common Stock, including an exercise of stock options and multiple 10b5-1 sales in late June 2026.

Rhea-AI Filing Summary

GLUE affiliate submitted a Form 144 notice disclosing proposed and recent sales of Common Stock, including an exercise of stock options and multiple 10b5-1 sales in late June 2026. The filing lists an option exercise of 5,407 shares on 06/30/2026 and 10b5-1 dispositions of 30,000, 11,845, and 6,000 shares on 06/24/2026, 06/23/2026, and 06/29/2026 respectively, with gross proceeds shown for each sale.

Insights

Insider Transactions Analyst

Filed Form 144 shows option exercise plus prearranged 10b5-1 sales in late June 2026.

The notice records an exercise of stock options for 5,407 shares on 06/30/2026 and three 10b5-1 sales: 30,000, 11,845, and 6,000 on the dates shown. Each sale lists gross proceeds in dollars in the excerpt.

These entries are procedural disclosures of affiliate trading activity; the excerpt does not describe who receives proceeds or any change to company capital structure. Subsequent filings could show final sale settlement details or additional disclosures.

Key Figures

Option exercise: 5,407 shares 10b5-1 sale: 30,000 shares 10b5-1 sale: 11,845 shares +1 more

4 metrics

Option exercise 5,407 shares exercise of stock options on 06/30/2026

10b5-1 sale 30,000 shares sale on 06/24/2026; proceeds $642,681.00

10b5-1 sale 11,845 shares sale on 06/23/2026; proceeds $239,522.50

10b5-1 sale 6,000 shares sale on 06/29/2026; proceeds $137,700.00

Key Terms

10b5-1 Sales, Exercise of Stock Options, Form 144

3 terms

10b5-1 Sales regulatory

"10b5-1 Sales for FILIP JANKU 321 Harrison Avenue, Suite 900"

10b5-1 sales are pre-arranged stock-trading plans that let company insiders automatically buy or sell shares according to a fixed schedule or formula, even if they later learn confidential information. Think of it as setting up an automatic thermostat for trades: it creates a clear, documented path that can protect insiders from insider-trading accusations and gives investors a signal about predictable insider activity—though it can also simply be a way for insiders to diversify or raise cash.

Exercise of Stock Options financial

"Common | 06/30/2026 | Exercise of Stock Options | Issuer"

Form 144 regulatory

"Filer Information | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does GLUE's Form 144 disclose about the June 2026 trades?

It discloses an option exercise of 5,407 shares on 06/30/2026 and three 10b5-1 sales of 30,000, 11,845, and 6,000 shares. The filing includes gross dollar proceeds for each sale in the excerpt.

Who executed the 10b5-1 sales reported in GLUE's filing?

The excerpt identifies the seller as executing 10b5-1 sales for Filip Janku with an address listed. The filing shows transaction dates and share counts but does not state settlement recipients beyond the seller name.

Does the Form 144 show proceeds for the June 2026 sales of GLUE stock?

Yes; the excerpt lists gross proceeds for each 10b5-1 sale: $642,681.00 for 30,000 shares, $239,522.50 for 11,845 shares, and $137,700.00 for 6,000 shares. The exercise entry lists cash as consideration.

Does the filing indicate whether GLUE will receive proceeds from these transactions?

The excerpt shows an exercise of stock options described with 'Issuer' and 'Cash' but does not detail whether the company will retain proceeds. The document does not state a use of proceeds or beneficiary explicitly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/30/2026 - 04:38 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001862930
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Monte Rosa Therapeutics, Inc.
SEC File Number	001-40522
Address of Issuer	321 Harrison Avenue, Suite 900 Boston MASSACHUSETTS 02118
Phone	617-949-2643
Name of Person for Whose Account the Securities are To Be Sold	FILIP JANKU
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	5407	129227.30	84479418	06/30/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/30/2026	Exercise of Stock Options	Issuer			5407	06/30/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for FILIP JANKU 321 Harrison Avenue, Suite 900 Boston MA 02118	Common	06/29/2026	6000	137700.00
10b5-1 Sales for FILIP JANKU 321 Harrison Avenue, Suite 900 Boston MA 02118	Common	06/24/2026	30000	642681.00
10b5-1 Sales for FILIP JANKU 321 Harrison Avenue, Suite 900 Boston MA 02118	Common	06/23/2026	11845	239522.50

144: Remarks and Signature

Remarks
Date of Notice	06/30/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/04/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Filip Janku
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)